



Figure S1



**Figure S1** B cell infiltrate in PDA

**(A)** Scatter dot plots comparing cytokine concentrations (as indicated) in peritumoral stroma PDA tissue of patients (n=48 for CXCL9, CXCL10, IL7, IL10, IL17, IFNG, CXCL12, VCAM1, LTA, CCL3; n=26 for CCL4) with stratification in "B cell high" and "B cell low".


Figure S1



**Figure S1** B cell infiltrate in PDA

**(B)** Scatter dot plots comparing cytokine concentrations (as indicated) in peritumoral stroma PDA tissue of patients (n=48 for IFNG, TNFA, IL2, IL12, IL12B, IL1B, IL4, IL9, IL10; n=31 for IL4) with stratification in "B cell high" and "B cell low".


Figure S2



**Figure S2** Formation of TLS and their association with immune phenotypes and patient outcome

**(A)** Scatter dot plots comparing the density of immune cells (as indicated) in peritumoral stroma of PDA patients with "TLS" versus "No TLS". Information on immune cell density was available as follows: CD3<sup>+</sup> (n=51), CD4<sup>+</sup> (n=51), NKp46<sup>+</sup> (n=47), FoxP3<sup>+</sup> (n=51), CD163<sup>+</sup> (n=48).


Figure S2



**Figure S2** Formation of TLS and their association with immune phenotypes and patient outcome

**(B)** Scatter dot plots comparing cytokine concentrations (as indicated) in peritumoral stroma PDA tissue of patients (n=51 for CXCL9; n=49 for CXCL10, IL7, IL10, IL17, IFNG, CXCL12, LTA, CCL3; n=47 for VCAM1; n=26 for CCL4) with stratification in "TLS" and "No TLS".

Figure S2



**Figure S2** Formation of TLS and their association with immune phenotypes and patient outcome  
**(C)** Kaplan-Meier survival plot of PDA patients with high versus low CD21 gene expression (n=91/n=92). The data was obtained from the Xena platform [11].